Please login to the form below

Not currently logged in
Email:
Password:

TCR-T

This page shows the latest TCR-T news and features for those working in and with pharma, biotech and healthcare.

BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform

BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform

BioNTech is looking to extend its presence in the cell therapy space, announcing a planned acquisition of Gilead company Kite’s solid tumour neoantigen T cell receptor (TCR) R&D platform ... This differs from CARs, which recognise antigens on the cell

Latest news

  • GSK pays $50m upfront to tap Immatics’ cell therapy platform GSK pays $50m upfront to tap Immatics’ cell therapy platform

    Under the terms of the latest deal, Immatics will be in charge of taking the TCR projects through to the stage where a clinical candidate has been identified, with GSK taking ... TCR therapies are emerging as a new type of cell therapy that involves

  • Newly-listed BioNTech buys Neon to boost cell therapy assets Newly-listed BioNTech buys Neon to boost cell therapy assets

    BioNTech said the deal would expand its CAR-T and T cell receptor (TCR) pipeline, allowing it to tap into Neon’s portfolio of cancer neoantigens – newly formed antigens that have ... executive. “I am particularly excited about the adoptive T cell

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    Immatics’ XPRESIDENT technology and XCEPTOR TCR discovery and engineering platform are tailored to developing effective TCR-T cell therapies. ... Celgene will also be able to manufacture and gain worldwide commercialisation rights to the TCR-T cell

  • CAR-T player Autolus seeks $100m from follow-on financing CAR-T player Autolus seeks $100m from follow-on financing

    The Nasdaq-listed biotech company - considered one of the brightest prospects of the UK biotech sector thanks to its promising CAR-T and TCR technologies – says it will use the net ... approved CAR-T Kymriah (tisagenlecleucel) – which recently

  • Roivant forms Asian cell therapy ‘vant’, with Medigene’s help Roivant forms Asian cell therapy ‘vant’, with Medigene’s help

    The deal with Medigene covers rights to a research-stage T cell receptor (TCR) against tumour antigen NY-ESO-1 and Medigene’s dendritic cell vaccine targeting WT-1 and PRAME ... The two companies work also together on two additional TCR projects that

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch September 2016 Deal Watch September 2016

    1, 695. Medigene /Bluebird bio. Licence. Development and commercialisation of T cell receptor (TCR) immunotherapies against four targets, P1 ready, includes upfront of $15m. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies

  • Deal Watch February 2016 Deal Watch February 2016

    The ARCUS technology enables the production of CAR T-cells derived from healthy donors (i.e. ... licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting

  • Pharma deals in June 2015 Pharma deals in June 2015

    therapeutic strategies, and initially on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies. ... Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2). ... Collaboration. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...